Drug Screening Market Size And Growth In 2026: Key Factors Shaping Future Demand
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Drug Screening Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The drug screening market has experienced substantial expansion in recent times. The market is anticipated to expand from $9.72 billion in 2025 to $11.18 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.0%. Historically, this growth was driven by factors such as the rise in workplace drug testing initiatives, the broadening of clinical trial endeavors, heightened screening demands from law enforcement, the proliferation of diagnostic laboratories, and the wider accessibility of rapid test kits.
The drug screening market size is projected to experience substantial growth over the next few years. It is anticipated to expand to $19.2 billion in 2030, with a compound annual growth rate (CAGR) of 14.5%. This growth during the forecast period is driven by factors such as the increasing adoption of AI-enabled screening analytics, a rising demand for portable drug testing devices, the expansion of regulatory drug compliance testing, the growing utilization of real-time reporting systems, and innovations in multi-panel drug screening. Significant trends expected in the forecast period include the increasing uptake of rapid drug testing kits, the rising use of automated laboratory screening systems, the growing integration of digital reporting solutions, the expansion of point-of-care drug testing, and an enhanced focus on high-accuracy detection.
Get A Free Sample Report With In-Depth Market Insights:
Drug Screening Market Growth Drivers: What’s Behind The Acceleration?
The increasing consumption of drugs and alcohol is anticipated to propel the expansion of the drug screening market in the coming period. Drug addiction is defined as a condition impacting an individual’s brain and behavior, leading to an inability to manage the use of either legal or illegal drugs or medications. Substances such as alcohol, marijuana, and nicotine are also classified as drugs. As addiction to drugs and alcohol rises, the likelihood of contracting diseases increases, which in turn fuels the necessity for drug screening. For instance, according to a June 2025 report from the Austria-based United Nations Office on Drugs and Crime, 316 million individuals, representing six percent of the population aged 15 to 64, used a drug (excluding alcohol and tobacco) in 2023. Cannabis remained the most prevalent drug, with 244 million users, followed by opioids at 61 million, amphetamines at 30.7 million, cocaine at 25 million, and “ecstasy” at 21 million. Therefore, the escalating intake of drugs and alcohol is a significant driver of growth for the drug screening market during the forecast period.
Drug Screening Market Segment Trends And Revenue Contributors
The drug screening market covered in this report is segmented –
1) By Products: Rapid Testing Devices, Consumables, Other Products
2) By Sample Type: Oral Fluid Sample, Hair Sample, Urine Sample, Breath Sample, Other Sample Types
3) By End User: Drug Testing Laboratories, Workplaces, Criminal Justice and Law Enforcement Agencies, Hospitals, Drug Treatment Centers, Individual Users, Pain Management Centers, Schools and Colleges
Subsegments:
1) By Rapid Testing Devices: Urine Drug Test Kits, Saliva Drug Test Kits, Blood Drug Test Devices, Instant Test Strips
2) By Consumables: Reagents and Assays, Sample Collection Devices, Calibration Standards
3) By Other Products: Laboratory Equipment, Software Solutions, Storage and Transport Solutions
Drug Screening Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies active in the drug screening market are increasingly concentrating on forming strategic alliances and cooperative ventures to strengthen their financial standing, enhance their product portfolios, and broaden their geographic reach. A strategic collaboration entails an agreement between two or more entities to pursue a common set of objectives while each organization maintains its independent status. For instance, in February 2025, Neopharma Technologies, a Canada-based drug testing company, and Impairment Science, a United States-based cognitive assessment company, announced a strategic partnership designed to revolutionize drug and impairment testing. This collaboration merges Neopharma’s NEOVAULT platform, which digitally processes and reports rapid drug test results, with Impairment Science’s DRUID cognitive impairment assessment, an AI-driven tool for evaluating functional impairment. By integrating these two distinct technologies, the partnership aims to elevate the accuracy and relevance of drug screening, providing real-time insights into both drug presence and functional impairment. This joint effort could potentially enhance workplace safety, regulatory compliance, and decision-making in safety-sensitive environments through the application of AI and digital reporting technologies.
Drug Screening Market Top Companies Driving Competitive Growth
Major companies operating in the drug screening market are Laboratory Corporation, Quest Diagnostics Incorporated, OraSure Technologies Inc., Alfa Scientific Designs Inc., Abbott Laboratories, Thermo Fisher Scientific Inc., Drägerwerk AG & Co. KGaA, LifeLoc Technologies Inc., MPD Inc., Omega Laboratories Inc., Premier Biotech Inc., Psychemedics Corporation, F. Hoffmann-La Roche Ltd., Shimadzu Corporation, Siemens Healthineers AG, Medtox Scientific Inc., American Screening Corporation, Clinical Reference Laboratory Inc., Express Diagnostics International Inc., Global Drug Testing Services, Kroll Laboratory Specialists Inc., Medscreen Laboratories, National Screening Centers Inc., American Bio Medica Corporation, Mayo Clinic Laboratories, ACM Global Laboratories, Intertek Group plc, Eurofins Scientific SE
View The Full Drug Screening Market Report:
Drug Screening Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the drug screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the drug screening market during the forecast period. The regions covered in the drug screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
